Capricor Therapeutics Faces Securities Fraud Class Action Suit
Capricor Therapeutics Under Legal Scrutiny
New legal challenges have emerged for Capricor Therapeutics, Inc. (NASDAQ: CAPR) as a shareholder has taken legal action by filing a securities class action lawsuit. This lawsuit aims to address concerns that investors who acquired shares within a specified time frame may have suffered financial losses due to misrepresentations regarding the company’s operations.
Overview of the Lawsuit
The lawsuit targets all investors who purchased or acquired Capricor shares between specific dates. Shareholders are encouraged to consider their legal rights and potential options available in this scenario. The legal action comes in the wake of alleged inaccuracies regarding the company’s key trial results for its leading novel cell therapy for cardiomyopathy.
Who Should Consider Joining the Lawsuit?
If you are an investor or have an interest in Capricor Therapeutics, it is essential to know whether you qualify as a member of this class action. Questions posed by the legal representatives include whether you owned shares of Capricor during the relevant period, and if you experienced any monetary losses as a consequence of the company’s actions.
Understanding the Allegations
Allegations in the lawsuit center on misleading statements made by the company concerning the safety and efficacy of its therapeutic candidate, deramiocel. This treatment is intended for addressing cardiomyopathy associated with Duchenne muscular dystrophy, a serious condition that affects muscle function.
Implications for Shareholders
For shareholders interested in participating in the class action, there are deadlines and requirements to be aware of. Filing to serve as the lead plaintiff must be completed by a particular date, while those who choose not to take action can remain absent class members without needing to engage in the litigation directly. This aspect highlights both the opportunities and risks present in the lawsuit.
Potential Costs and Fees
One key reassurance for involved shareholders is that all legal representation in this class action will be conducted on a contingency fee basis. Therefore, shareholders will not incur any fees or expenses unless the lawsuit secures a favorable outcome for them.
Firm Background and Achievements
Bernstein Liebhard LLP, the law firm representing the shareholders, has a notable record, having recovered significant amounts for clients over the years. The firm also routinely represents large public and private pension funds, enhancing its credibility and experience in handling complex class-action lawsuits.
Contact Information
For those interested in learning more or discussing their individual situations, they can contact the Investor Relations Manager, Peter Allocco, directly. His office is equipped to provide detailed answers related to the class action process and what it means for existing and potential investors.
Frequently Asked Questions
What is the basis of the lawsuit against Capricor Therapeutics?
The lawsuit is based on allegations that the company misrepresented important data related to its drug, deramiocel, leading to financial losses for shareholders.
Who can join the class action lawsuit?
Investors who purchased or acquired shares of Capricor Therapeutics during the specified period are eligible to join the lawsuit.
What are the costs associated with joining the lawsuit?
There are no upfront fees for shareholders participating in the lawsuit; representation is provided on a contingency basis.
How can shareholders participate in the lawsuit?
Shareholders interested in participating can consult under the guidance of Bernstein Liebhard LLP for assistance in filing any necessary papers.
What happens if I choose not to participate?
If a shareholder chooses not to engage, they can remain an absent class member and will not be required to take any direct actions during the litigation.
About The Author
Contact Hannah Lewis privately here. Or send an email with ATTN: Hannah Lewis as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.